{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHMP"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"CHMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"Champion Industries, Inc.","latestPrice":0.0001,"timestamp":1744731720000,"preClose":0.0001,"halted":0,"volume":0,"delay":15,"floatShares":0,"shares":55857,"eps":-23.033406,"marketStatus":"Trading","change":0,"latestTime":"04-15 11:42:00 EDT Delay","open":0.0001,"high":0.0001,"low":0.0001,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1744747200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.0001,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","floatShares":0,"roa":"-1.87%","roe":"-49.45%","lyrEps":-23.033406,"shares":55857,"dividePrice":0,"high":0.0001,"amplitude":0,"preClose":0.0001,"low":0.0001,"week52Low":0.0001,"pbRate":"0.00","psRate":"0.00","week52High":0.0001,"institutionHeld":0,"latestPrice":0.0001,"eps":-23.033406,"divideRate":0,"volume":0,"delay":15,"ttmEps":-23.033406,"open":0.0001,"prevYearClose":0.0001,"prevWeekClose":0.0001,"prevMonthClose":0.0001,"prevQuarterClose":0.0001,"fiveDayClose":0.0001,"twentyDayClose":0.0001,"sixtyDayClose":0.0001},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CHMP\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHMP\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524784382","title":"Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2524784382","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524784382?lang=en_us&edition=fundamental","pubTime":"2025-04-04 21:46","pubTimestamp":1743774360,"startTime":"0","endTime":"0","summary":"This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy and the expanded use of AstraZeneca’s AZN blockbuster cancer drug, Imfinzi. J&J’s JNJ bankruptcy strategy to settle talc lawsuits failed for the third time. The European Commission approved Pfizer’s PFE respiratory syncytial virus vaccine, Abrysvo, for use in adults aged 18 through 59 years.Here's a recap of the week’s most important stories.Texas Court Rejects J&J’s Bankruptcy Attempt to End Talc Suits. A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the third time. In September, J&J, via a subsidiary called Red River Talc, filed for voluntary bankruptcy in the Southern District of Texas after it received the support of around 83% of current claimants for the proposed bankruptcy plan, which was above the 75% required by the U.S. bankruptcy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-fda-nod-134600557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2430703178.SGD","SNY","LU1778281490.HKD","LU0289739699.SGD","IE00B1BXHZ80.USD","IE00BVYPNW00.USD","LU0985320562.USD","LU1261432733.SGD","LU1674673691.USD","SG9999013999.USD","LU1267930813.SGD","LU1894683264.USD","CHMP","LU0070302665.USD","LU0225284248.USD","LU1585245621.USD","LU2592432038.USD","LU2602419157.SGD","LU0345770993.USD","IE00BSNM7G36.USD","IE00B3PB1722.GBP","LU0306807586.USD","LU0889566641.SGD","BK4532","JNJ","LU1244550221.USD","LU0345770308.USD","BK4533","LU1732799900.SGD","LU2129689605.HKD","AZN","LU0114720955.EUR","LU2129689431.USD","PFE","IE00B2B36J28.USD","SG9999001440.SGD","LU0868494617.USD","LU2133065610.SGD","LU0912757837.SGD","LU0320765992.SGD","NVS","LU0058720904.USD","IE00BJT1NW94.SGD","BK4585","LU2112291526.USD","BK4599","SG9999001176.USD","IE00BLSP4239.USD","LU1430594728.SGD","LU1280957306.USD"],"gpt_icon":1},{"id":"2524259864","title":"Akebia announces CHMP positive opinion for XOANACYL","url":"https://stock-news.laohu8.com/highlight/detail?id=2524259864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524259864?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:12","pubTimestamp":1743682322,"startTime":"0","endTime":"0","summary":"Akebia (AKBA) Therapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positiv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/akebia-announces-chmp-positive-opinion-for-xoanacyl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/akebia-announces-chmp-positive-opinion-for-xoanacyl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4087","AKBA","CHMP"],"gpt_icon":0},{"id":"2524725981","title":"Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa","url":"https://stock-news.laohu8.com/highlight/detail?id=2524725981","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524725981?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April 03, 2025  -- Akebia Therapeutics, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency  has adopted a positive opinion recommending the European Commission  to approve XOANACYL  for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease .“We congratulate our partner Averoa on a positive step toward securing EMA approval for XOANACYL, and we will continue to support their efforts to deliver a treatment for complications of kidney disease to patients in Europe,” said John P. Butler, Chief Executive Officer of Akebia.The EC will review the CHMP recommendation, and a final decision is expected in approximately two months.About Akebia TherapeuticsAkebia Therapeutics, Inc.is a fully integrated biopharmaceutical company with the purpose to bet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/akebia-therapeutics-announces-positive-opinion-120000568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AKBA","CHMP","EC","MDCO","BK4201","BK4139","BK4087"],"gpt_icon":0},{"id":"2524917146","title":"AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2524917146","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524917146?lang=en_us&edition=fundamental","pubTime":"2025-04-01 21:31","pubTimestamp":1743514260,"startTime":"0","endTime":"0","summary":"AstraZenecaAZN announced that the FDA has approved its blockbuster drug, Imfinzi, for a bladder cancer indication in the United States.Imfinzi is approved in combination with gemcitabine and cisplatin as a neoadjuvant treatment for muscle-invasive bladder cancer , a type of bladder cancer that has spread into the muscle wall of the bladder. The regulatory filing for the drug was reviewed under the FDA’s Priority Review Pathway. This marks the first approval for Imfinzi for a bladder cancer indication.AstraZeneca’s Imfinzi, either as a monotherapy or in combination with chemotherapy, is presently approved for stage III non-small cell lung cancer, extensive-stage small cell lung cancer, locally advanced or metastatic biliary tract cancer and endometrial cancer that is mismatch repair deficient and in combination with Imjudo in unresectable hepatocellular carcinoma in some countries. The drug has also recently been approved for limited-stage small cell lung cancer in the United States and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazenecas-imfinzi-gets-fda-nod-133100339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1559883803.SGD","LU2456880835.USD","LU2462157665.USD","LU0889565916.HKD","BK4588","LU2417539215.USD","BK4532","BK4568","LU2236285917.USD","AZN","BK4087","LU0109394709.USD","CORT","BK4585","DVAX","CHMP","BK4007","BAYRY","LU0320765992.SGD","LU1829250122.USD","BK4139","LU0566484027.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":32,"pageCount":1,"totalSize":126,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHMP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHMP\",market:\"US\",delay:false,,,undefined,":{}}}